Navigation Links
GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA

ARLINGTON, Va., March 14 /PRNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger regarding the nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of the U.S. Food and Drug Administration (FDA).

"GPhA stands ready to work with Dr. Margaret Hamburg on the critical issues facing the Agency as it carries out its mission to protect the public health. Dr. Hamburg's outstanding experience both in government and the health care arena make her an excellent choice to lead the FDA. Now more than ever, FDA needs a strong, smart manager and Dr. Hamburg answers that call.

"As Deputy Commissioner, Dr. Joshua Sharfstein brings exceptional knowledge of what it takes to ensure the safety and efficacy of the medicines that Americans rely on to improve their health. His commitment to protecting the public health is stellar. As Commissioner and Deputy Commissioner, Drs. Hamburg and Sharfstein will work to give FDA scientists the resources they desperately need to uphold the Agency's gold standard of quality and safety.

"With Americans growing increasingly concerned about paying for needed medicines as the economy continues to struggle, it is critical that consumers have access to safe and affordable generic and biogeneric medicines. FDA scientists and reviewers are working hard every day to bring generic medicines to market, but the FDA's resources are simply stretched too thin and long-existing barriers to access must be eliminated. With generics saving government and consumers billions of dollars annually, we look forward to working with Dr. Hamburg to increase investments in the Agency and remove barriers that are keeping affordable medicines from getting to patients.

"The time has also come for Congress to give FDA the authority and flexibility to create a workable biogenerics approval pathway. President Obama stated in his budget proposal his desire to move the process forward and his action was followed by the bipartisan consensus bill introduced by Chairman Waxman, and Representatives Deal, Pallone and Emerson earlier this week. Dr. Hamburg's leadership will be instrumental in this effort.

"We also look forward to working with Drs. Hamburg and Sharfstein on a host of other important Agency issues including strengthening the foreign inspection system and addressing the proliferation of carve-out legislation being introduced in state capitols across the country. As we celebrate the 25th anniversary of the passage of the landmark Hatch-Waxman Act, the generic industry is rolling up its sleeves to work with the new FDA leadership, the Obama Administration and Congress in creating history again through passage of biogenerics legislation and strengthening our health care system."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit

SOURCE Generic Pharmaceutical Association (GPhA)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
2. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
3. Pelosi Statement on President Obamas Executive Order on Stem Cell Research
4. AHIP Statement on White House Health Care Summit
5. Change to Win Statement on White House Health Care Forum
6. Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California, Regarding President Obamas Healthcare Summit
7. AAJ Statement on Supreme Court Decision in Favor of Diana Levine
8. NJLRA Statement on Todays U.S. Supreme Courts Decision in Wyeth v. Levine
9. AAHSA Statement on Senate Special Committee on Aging Hearing, Health Reform in an Aging America
10. Pelosi Statement on President Obamas Nomination of Governor Sebelius as Secretary of HHS
11. AHIP Statement on Governor Sebelius and Nancy-Ann DeParle
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
Breaking Medicine Technology: